
Catena Biosciences crafts novel therapeutics by rapidly coupling proteins for diverse medical needs.
Catena Biosciences specializes in innovative protein coupling technology to develop advanced therapeutics. Their platform enables the attachment of any two soluble proteins using an enzyme and native amino acids, without size or complexity restrictions. This versatile approach has applications in modifying cancer-specific antibodies, CRISPR proteins, and cell surfaces, offering potential for a wide range of medical treatments.
The company's vision is to revolutionize therapeutic development by making biologic construction as flexible as small molecule synthesis. Catena's technology allows for the creation of modular protein therapeutics, expanding possibilities in antibody-drug conjugates and functional antibody engineering. This approach aims to overcome current limitations in biologic structures, potentially opening new avenues for treating various medical conditions.

BrickBio
brickbio.com

Modulari-T
modularit.bio

Protillion Biosciences
protillion.com

BigHat Biosciences
bighatbio.com

CasTag Biosciences

EpiBiologics
epibiologics.com

AI Proteins
aiproteinstx.com

Adaptyv Biosystems
adaptyvbio.com

Nabla Bio
nabla.bio

Cisterna Biologics
cisternabx.com

Andson Biotech
andsonbiotech.com

Proteinea
proteinea.com

SynsoryBio
synsorybio.com

LiliumX
liliumx.com

Medium Biosciences
medium.bio
Companies similar to Catena Biosciences include BrickBio, Modulari-T, Protillion Biosciences and BigHat Biosciences.
Catena Biosciences was founded in 2020.
Catena Biosciences' headquarters is located in Berkeley, CA, US.
Catena Biosciences' most recent funding round was for $5M (USD) in August 2021.
As of Aug 1, 2021, Catena Biosciences has raised a total of $5.7M (USD).
Catena Biosciences has 12 employees as of Feb 4, 2024.